Ointment vehicle

DRUG6 trials

Sponsors

Healthpoint, Pfizer, LEO Pharma, Bayer

Conditions

Alopecia AreataHealthyPsoriasisPsoriasis Vulgaris

Phase 1

Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment

CompletedNCT00645164

HealthpointHealthy

Start: 2008-03-31End: 2008-06-30Updated: 2010-06-08

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

TerminatedNCT02936492

Start: 2016-10-24End: 2017-10-16Updated: 2017-11-08

Phase 2

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

CompletedNCT00755196

PfizerPsoriasis

Start: 2008-09-30End: 2008-12-31Updated: 2017-03-06

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

CompletedNCT01300052

PfizerPsoriasis

Start: 2011-01-26End: 2011-06-06Updated: 2017-04-17

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

CompletedNCT01536886

LEO PharmaPsoriasis Vulgaris

Start: 2012-05-31End: 2012-11-30Updated: 2025-03-07

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

TerminatedNCT03325296

LEO PharmaAlopecia Areata

Start: 2017-10-30End: 2018-05-16Updated: 2025-02-24

Related Papers

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials.

2020-08-123 citations

PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.

2020-05-169 citations

Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam

Journal of the European Academy of Dermatology and Venereology2018-12-0623 citations